Velcade Injection, Powder, Lyophilized, For Solution
Product Images NDC 63020-049

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Velcade (NDC 63020-049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure (Velcade 01)

Figure (Velcade 01)
FDA Label Image

Figure (Velcade 02)

Figure (Velcade 02)
FDA Label Image

Chemical Structure (Velcade 03)

Chemical Structure (Velcade 03)
FDA Label Image

Figure 1 (Velcade 04)

Figure 1 (Velcade 04)
FDA Label Image

Figure 2 (Velcade 05)

Figure 2 (Velcade 05)
This is a table that shows the number of patients remaining after a certain time point and the corresponding p-values from a log-rank test. The treatment options being compared are Bortezomib and Dexamethasone. The numbers in the table seem to represent the number of patients who survived after the given time, grouped by a certain range.*
FDA Label Image

Figure 3 (Velcade 06)

Figure 3 (Velcade 06)
FDA Label Image

Figure 4 (Velcade 07)

Figure 4 (Velcade 07)
This appears to be a graph showing survival rates for two different treatment groups over time. The names of the treatment groups are not available, but they are labeled as "VGR-CAP" and "R-CHOP". The graph shows the percentage of subjects still alive at different time points from the start of the study, and includes a Hazard Ratio value with a confidence interval. It seems like the graph is showing that the survival rate for the VGR-CAP group is higher than the survival rate for the R-CHOP group.*
FDA Label Image

Figure 5 (Velcade 08)

Figure 5 (Velcade 08)
VELCADE® is a prescription medicine used to treat multiple myeloma and mantle cell lymphoma. It contains 3.5 mg of bortezomib and 35 mg of mannitol per vial. It should be stored at 25°C (77°F) and protected from light. Dosage information is available in the accompanying package insert.*
FDA Label Image

Logo (Velcade 09)

Logo (Velcade 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.